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Background: Malnutrition is an independent risk factor of postoperative morbidity and mortality and it’s observed
in 20 to 50% of surgical patients. Preoperative interventions to optimize the nutritional status, reduce postoperative
complications and enteral nutrition has proven to be superior to the parenteral one. Moreover, regardless of the
nutritional status of the patient, surgery impairs the immunological response, thus increasing the risk of
postoperative sepsis. Immunonutrition has been developed to improve the immunometabolic host response in
perioperative period and it has been proven to reduce significantly postoperative infectious complications and
length of hospital stay in patients undergoing elective gastrointestinal surgery for tumors. We hypothesize that a
preoperative oral immunonutrition (ORAL IMPACT®) can reduce postoperative morbidity in liver resection for cancer.
Methods/design: Prospective multicenter randomized placebo-controlled double-blind phase IV trial with two
parallel treatment groups receiving either study product (ORAL IMPACT®) or control supplement (isocaloric
isonitrogenous supplement - IMPACT CONTROL®) for 7 days before liver resection for cancer. A total of 400 patients
will be enrolled. Patients will be stratified according to the type of hepatectomy, the presence of chronic liver
disease and the investigator center. The main end-point is to evaluate in intention-to-treat analysis the overall
30-day morbidity. Secondary end-points are to assess the 30-day infectious and non-infectious morbidity, length of
antibiotic treatment and hospital stay, modifications on total food intake, compliance to treatment, side-effects of
immunonutrition, impact on liver regeneration and sarcopenia, and to perform a medico-economic analysis.
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Discussion: The overall morbidity rate after liver resection is 22% to 42%. Infectious post-operative complications
(12% to 23%) increase the length of hospital stay and costs and are responsible for a quarter of 30-day mortality.
Various methods have been advocated to decrease the rate of postoperative complications but there is no
evidence to support or refute the use of any treatment and further trials are required. The effects of preoperative
oral immunonutrition in non-cirrhotic patients undergoing liver resection for cancer are unknown. The present trial
is designed to evaluate whether the administration of a short-term preoperative oral immunonutrition can reduce
postoperative morbidity in non-cirrhotic patients undergoing liver resection for cancer.
Trial registration: Clinicaltrial.gov: NCT02041871.
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Hepatic resection is the treatment of choice for selected
patients with benign and malignant hepatobiliary dis-
ease. Malignant tumors represent about 63 to 90% of
whole liver surgery [1,2] and the most common diagno-
sis is metastatic colorectal cancer [3,4]. Primary hepatic
and biliary cancers account for about 20% of liver resec-
tion, of which hepatocellular carcinoma (HCC) is the
most common [1]. Only in 13 to 30% of hepatectomies
an underlying liver disease, such as cirrhosis, is present.
Over the past decade, many large series have docu-
mented an improvement in perioperative results, with
operative mortality rates after liver resection typically
less than 5% in high-volume centers. Actually liver re-
sections are associated with about 3.5% risk of 30-days
mortality [5]. The overall morbidity rate, reported in dif-
ferent series, is from 22 to 42% of which 10% to 15% are
major post-operative complications resulting in a pro-
longation of hospital stay [1,6,7]. The most common
complications are bile leak, post-operative infections,
liver failure, renal failure, cardio-vascular complications
and hemorrhage. About 12% to 23% of patients undergo-
ing liver resection develop infectious complications includ-
ing chest and urinary tract infections, wound infections
and infected abdominal collections [6,8]. The infectious
complications account for approximately a quarter of 30-
day mortality.
The negative impact of postoperative complications
(POC), and specially infectious complications, on long-
term outcomes after liver surgery has been widely re-
ported for colorectal liver metastases (CLM) as well as
for HCC [7,9-12]. Various methods have been advocated
to decrease the rate of infectious postoperative compli-
cations after liver resections. These include systemic in-
terventions such as antibiotics in peri-operative period
[8,13], topical interventions such as povidone iodine gel
at the time of wound closure [14] and methods to im-
prove general health and the immunity of the individual
such as prebiotics and probiotics [15,16] and the recom-
binant bactericidal-permeability increasing protein in
peri-operative period [17]. A recent meta-analysis of theCochrane collaboration [18] has selected 7 randomized
clinical trials from more than 1800 records identified in
the literature, to determine benefits and harms of the
different interventions in decreasing the infectious com-
plications and improving the outcomes after liver resec-
tions. In any of the compared interventions there was no
significant difference between the two groups in terms
of mortality, numbers of serious adverse events and in-
tensive therapy unit stay. Author’s conclusion is that till
now there is no evidence to support or refute the use of
any treatment and further trials are required.
To date, the effects of preoperative oral immunonutri-
tion (ORAL IMPACT®) in non-cirrhotic patients under-
going liver resection for cancer are unknown. As seen in
major gastrointestinal surgery, this treatment could sig-
nificantly reduce postoperative infectious complications,
length of hospital stay and care costs [19-22]. Therefore
the present trial is designed to evaluate whether the
administration of a short-term preoperative oral immu-
nonutrition can reduce postoperative morbidity in non-
cirrhotic patients undergoing liver resection for cancer.
Methods/design
Protocol overview
The PROPILS trial is a prospective multicenter random-
ized placebo-controlled double-blind phase IV trial with
two parallel treatment groups receiving either study prod-
uct (ORAL IMPACT®) or control supplement (isocaloric
isonitrogenous supplement - IMPACT CONTROL®) for
7 days before liver resection for cancer. Patients will be
stratified according to the type of hepatectomy (major or
minor hepatectomy), the presence of a chronic liver dis-
ease and the investigator center. The main end-point is to
determine in intention-to-treat analysis, the impact of
immunonutrition on the overall morbidity within 30 post-
operative days. Secondary end-points will be the impact of
immunonutrition on postoperative 30-day infectious and
non-infectious morbidity, length of antibiotic treatment,
length of hospital and ICU stay, modifications on total
food intake, compliance to treatment and side-effects
of immunonutrition, impact on liver regeneration and
ii)
iii)
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evaluate whether the supplementary costs associated to
preoperative immunonutrition could be counterbalanced
by its impact in care-costs.
This study is planned for a 32-month duration with a
30-month inclusion period and is registered on clinical-
trial.gov website (NCT02041871).
Inclusion criteria
PROPILS will include adult patients undergoing planned
elective liver resection for malignant tumors. The inclu-
sion criteria are as follows: 1) liver resection for malignan-
cies 2) including at least 1 segment resected or 3 wedge
resections 3) for patients who are over 18 years of age 4)
and provide a signed written consent form (Table 1).
Exclusion criteria
All patients who do not meet all the inclusion criteria
will be excluded. The other exclusion criteria include
liver surgery associated with biliary surgery or gastro-
intestinal surgery, liver cirrhosis, defined by transient
elastography (Fibroscan) or by liver biopsy, renal failure
defined by hemodialysis, pregnancy, history of hypersen-
sitivity to arginine, omega-3 fatty acids, or nucleotide,
inability to take oral nutrition and mental condition ren-
dering the subject unable to understand the nature, end-
points and consequences of the trial (Table 1).
Endpoints of trial
The primary endpoint of this trial will be the rate of
overall complications classified in grade II-III-IV or VTable 1 Selection criteria of study population
Inclusion criteria: - Patient older than 18 years old
- Planned elective liver resection for malignant
tumour
- At least 1 segment resected or 3 wedge resections
Exclusion criteria: - Patient younger than 18 years old
- Liver resection for benign lesion
- Liver resection associated with biliary tract surgery
- Liver resection associated with gastro-intestinal
surgery
- Cirrhosis, defined by transient elastography or
by liver biopsy
- Renal failure defined by hemodialysis
- Pregnancy
- History of hypersensitivity to arginine, omega-3
fatty acids, or nucleotides
- Inability to take oral nutrition
- Mental condition rendering the subject unable
to understand the nature, end-points and
consequences of the trialaccording to Dindo-Clavien classification [23] in the first
30 postoperative days (POD).
The secondary endpoints include:
i) The rate of infectious complications classified in
grade II, III, IV or V according to Dindo-Clavien
classification in the first 30 PODs including:
– Wound infection defined as any redness/
tenderness of surgical wound with discharge of
pus
– Abdominal abscess defined as deep collection of
pus
– Pulmonary tract infection characterized by
abnormal chest X-ray with fever (>38°C) and
WBC > 12.000 cells/mm3 and positive sputum or
bronco-alveolar lavage.
– Urinary tract infection defined as more than 107
microorganisms per mL of urine
– Bacteremia determined by two consecutive
positive blood cultures without shock
– Septic shock defined as positive blood cultures
with circulatory insufficiencyThe length of antibiotics treatment (in days)
The rate of non-infectious complications classified in
grade II, III, IV or V according to Dindo-Clavien
classification in the first 30 PODs including:
– Postoperative biliary leak defined by the
International Study Group of Liver Surgery
(ISGLS) [24] as a bilirubin concentration in the
drain fluid at least 3 times the serum bilirubin
concentration on or after postoperative day 3 or
as the need for radiologic or operative
intervention resulting from biliary collection or
bile peritonitis
– Post-operative liver failure defined according the’
50-50 criteria’ [25]: PT < 50% and total bilirubin
>50 μmol/ml at POD 5.
– Postoperative bleeding defined as the necessity of
blood transfusion (X2 units) [26]
– Respiratory failure characterized by the presence
of dyspnea and respiratory rate >35/min or PaO2
< 70 mmHg
– Circulatory insufficiency determined by unstable
blood pressure requiring use of extra fluids and/
or cardiac stimulants
– Renal dysfunction defined by increase of serum
urea and/or creatinine level (50% above baseline)
– Renal failure defined as the necessity of
hemodialysis
– Multiple Organ Dysfunction Syndrome (MODS)
characterized as a state of physiological
derangement in which organ function is not





Table 2 Composition of Oral Impact® and Impact Control®
supplement (in powder form)
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the fascia longer than 3 cmContent (1 sachet) Oral Impact® Impact Control®
(74 g) (74 g)
Energy content kCal 303 303
kJ 1275 1275
Proteins g 16.8 16.8
- L-Arginine g 3.8 0
- L-Arginine + Glutamine g 2.46 0
ARN g 0.45 0
Nitrogen g 3.3 3.3
Glucids g 40.2 40.2
Lipids g 8.3 8.3
- Omega-3 fatty acids g 1 0
- EPA-DHA g 1 0
Fibres g 3 3
Sodium mg 320 320
Potassium mg 402 402The length of hospital and ICU stay (in days)
Post-operative liver regeneration: all patients will
undergo 4 successive volumetric helical computed
tomography estimations of their liver volumes before
surgery (day 0) then at POD2 (day 16), POD10 (day
24) and POD30 (day 44). Preoperative measurement
of the future remnant liver will be performed using
as landmarks hepatic vascular structures, identified
by bolus injection of contrast, and the gallbladder.
Post-operative measurements will be performed for
the whole remnant liver and could be realized
without injection of contrast. A volumetric assessment
at POD 2 has been considered necessary to clearly
estimate the volume of remnant liver. Liver regeneration
at POD 10 (LR10) and 30 (LR30) are calculated by
using the following formula, after assuming that the
density of liver was close to 1:Calcium mg 240 240
Magnesium mg 69 69
Phosphorus mg 216 216
Chloride mg 360 360
Iron mg 3.6 3.6
Zinc mg 4.5 4.5LR10 ¼ ½ Liver volume at POD10ð Þ− Liver volume at POD2ð Þ½ 
100= Liver volume at POD2ð Þ
LR30 ¼ ½ Liver volume at POD30ð Þ− Liver volume at POD2ð Þ½ 
100= Liver volume at POD2ð ÞCopper mg 0.5 0.5
Manganese mg 0.6 0.6
Selenium ug 14 14
Fluoride mg 0.51 0.51
Iodine ug 45 45
Vitamin A ug 300 300
Vitamin D3 ug 2 2
Vitamin E mg 9 9Sarcopenia: all patients will undergo 2 helical
computed tomography estimations of psoas muscle
area at the level of L3-L4 before surgery (day 0) then
at POD30 (day 44).
) Estimation of modifications on total food intake,
compliance to immunonutrition treatment and side
effects of immunonutrition. During treatment
period, patients will be asked to fill in a formulary
with an evaluation of food intake per day.Vitamin K ug 20 20
Vitamin B1 mg 0.36 0.36
Vitamine B6 mg 0.45 0.45
Vitamin B9 ug 60 60
Vitamin B12 ug 1.7 1.7
Vitamin C mg 65 65
Osmolarity mOsm/L 477 477Treatments administered
After inclusion, patients will be randomized in two arms:
Arm A: immunonutrition (ORAL IMPACT®)
Arm B: isocaloric isoprotidic nutritional support
(IMPACT CONTROL) that has the same composition of
ORAL IMPACT, but does not contain the immunonutri-
ments (RNA, omega-3 fatty acids and arginine).
Oral immunonutrition (ORAL IMPACT®) and isocaloric
isonitrogenous control supplement (IMPACT CONTROL)
will be produced by NESTLE Nutrition, France.
In both groups, patients will be asked to drink three
74 g sachets of the product daily for 7 days before surgery.
Both study product (ORAL IMPACT®) and control prod-
uct (IMPACT CONTROL®) will be presented in the same
form and appearance (powder) including the packaging
material. The table below reports the composition of each
product (Table 2).Data collection and follow up
Patients will be followed-up for 44 days (POD30) and all
data collected by investigating physician will be entered
in a computerized case report forms. These recorded
data are summarized in Table 3.
Preoperative data including age, sex, medical history
and comorbidities, concomitant medication, preoperative
chemotherapy, history of liver surgery will be collected
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Medical history and comorbidity x
Concomittant medication x
Preoperative chemotherapy x
History of liver surgery x
ASA score x
Date of 1st consultation x
Operating date x
Type of liver resection x
Preoperative protein-energy malnutrition
Height x
Actual weight x x x x
BMI x x x x
Usual weight x
% of loss of weight in one and 6 months x
Albumin, prealbumin x x
MNA-SF (for patients > 70 years old) x
Sarcopenia (Psoas area on CT scan) x x x x
Compliance to immunonutrition treatment
Nutritional journal x
Liver function assessment
PT, INR x x x x x x x x
AST, ALT x x x x x x x x
GGT, PAL x x x x x x x x
Total and direct bilirubin x x x x x x x x
Platelets x x x x x x x x
Volumetric assessment of (future) remnant liver x x x x
Renal function assessment
Creatinine, urea x x x x x x x x
Sodium, potassium x x x x x x x x
Hemoglobin x x x x x x x x
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Table 3 Data collected during the study (Continued)
Biliary leak x
Length of hospital and ICU stay x
Length of antibiotic treatment x
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addition, an evaluation of the nutritional status of the pa-
tient will be realized by collecting the following data:
weight and BMI, albumin and prealbumin values, evalu-
ation of sarcopenia on CT Scan and, for patients older
than 70 years old, the MNA-SF test.
After randomization patients will receive either pre-
operative immunonutrition by Oral Impact® or preopera-
tive nutritional support without immunonutriments
(Impact control®) for 7 days before liver surgery. To evalu-
ate the compliance to preoperative immunonutrition, its
side effects and its impact on total food intake, patients
will be asked to fill out a nutritional journal during this
period.
Liver surgery will be performed by laparotomy or lapar-
oscopy according to the decision of the surgeon.
During postoperative period, monitoring of patients
will no differ from conventional monitoring after liver
surgery, including daily physical examination, blood ana-
lyses at postoperative day (POD) 1, POD3, POD5, POD7
and POD10, abdominal CT scan at POD10. In addition
abdominal CT scan will be done at POD2 to accurately as-
sess the liver volume immediately after hepatectomy. Mon-
itoring and management of postoperative complicationsFigure 1 Schema depicting the workflow of the study.are left to the discretion of the clinicians in charge of the
patient. All complications will be collected as soon as pos-
sible, during hospitalization, and classified according to
the classification of Dindo and Clavien [23].
Patients will be systematically reviewed at day 44 with
abdominal CT scan to identify postoperative complica-
tions after discharge, evaluate liver regeneration and sar-
copenia and to terminate their participation to the study
(Figure 1).
Concerning the radiological investigations performed
preoperatively and then on POD2, POD10 and POD30,
the assessment of remnant liver volumes and of sarcope-
nia, will be performed by a single radiologist.
Randomization
Patients will be randomized in blocks, with a distribution
of 1:1 for the control group and experimental group. The
block size will be random and will be informed in the re-
port of the study. Randomization will be stratified by in-
vestigator centre, type of hepatectomy and presence of an
underlying hepatopathy.
The randomization list will be established using the
software NQuery Advisor®v6.01, a validated system using
a generator of pseudo-random numbers, so that the
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predictable. The physician-investigator will enter data
for inclusion in computerized case report forms (eCRF),
implemented using the software “Cleanweb” (Telemedi-
cine technologies). The physician-investigator will be
able then to access the randomization module of the
software that will award the group in which the patient
is randomized. A unique identification alphanumeric
number will be assigned to each patient: “number of the
center (3 characters) – Number of inclusion in the cen-
ter (3 characters) - Initials of first and family names (1
and 1 characters) - randomization group”. Patients who
left the study keep their number included if it has
already been given. New patients will always receive a
new issue of inclusion.
The randomization list will not be known in advance
by the investigators. The statistical analysis and prepar-
ation of tables and graphs for the report of the study by
the statistician of the study will be blinded to the extent
possible. The unblinding may take place only after all
data has been entered into the database of the study, all
requests have been closed and the database has been fro-
zen by the Data Manager of the study.
If necessary, unblinding may be performed according
to validated procedures of the promoter. Access to
randomization codes during the phase of blinding will
be monitored and documented and the documentation
will be kept in the “CTMS (Clinical Trial Management
System)”.
Participating centers
Six French centers will participate in the study: the Paul
Brousse University Hospital in Villejuif, the Saint Antoine
University Hospital in Paris, the Mondor University Hos-
pital in Creteil, the Kremlin-Bicêtre University Hospital,




The hypothesis of this phase IV trial is that immunonu-
trition will reduce overall postoperative 30-day morbid-
ity rate. The sample size calculation is based on the
detection of significant difference in the primary end-
point parameter of the trial. We assumed a postoperative
complication rate of 36% in the conventional group
(Arm B) according with several studies about complica-
tion rate after liver surgery. A reduction of 33.3% would
be considered to indicate the efficacy of treatment. With
an expected complication rate of 24% in the immunonu-
trition group (Arm A), the sample size necessary for the
trial with a power of 80% and a one-sided significance
level of 0.05 was calculated to be 180 patients per group.
An assumed 10% drop-out rate in this trial (due to non-compliance, intolerance, etc.) will raise the sample size
to 198 patients per group. Therefore, at least a total of
400 patients (200×2) have to be included to the trial.
Statistical analyses
The statistical analysis will be based on the intention-to-
treat principle with one-sided test for the primary and
secondary endpoints. However, attempts will be made to
analyse “per protocol”, “completer”, and “intent-to-treat”
populations separately, when statistically appropriate. A
p < 0.05 will be considered as significant.
First of all, an establishment of patient flow chart ac-
cording with CONSORT 2010 statement [27] will be real-
ized. This one will describe precisely the progress through
the different phases of the randomized trial (enrolment,
intervention, allocation, follow-up and data analysis).
Secondary, a description of demographic and clinic
features of patients in the 2 groups will be calculated by
using valid number, frequency count and percentage for
categorical data and by using mean, standard deviation,
95%-confidence interval of the mean, minimum lower
quartile, median and upper quartile for continuous data.
To study primary end-point (that is the rate of postoper-
ative complication grading II, III, IV or V in Dindo-
Clavien’s classification), Pearson Chi-square test or Fisher’s
exact test will be used when appropriate.
To study secondary end-points, the Pearson Chi-square
or Fisher’s exact test will be used to compare categorical
variables between the 2 groups, and the independent-
samples t-test will be used to compare continuous vari-
ables. A multivariate analysis will complete this statistical
plan.
Ethical matters
This study is conducted according to the principles of
the declaration of Helsinki and the principles of the
Good Clinical Practices guidelines. This study was ap-
proved by ethics committee ‘Ile de France 1 (IDF1)’ of
the Hotel-Dieu Hospital on May 2013 under the regis-
tration number 2013-A00481-44. Approval from the ‘Ile
de France 1 (IDF1)’ ethics committee of the Hotel-Dieu
Hospital is sufficient for the 6 study centers (Paul
Brousse University Hospital, Saint Antoine University
Hospital, Mondor University Hospital, Pitié-Salpetrière
University Hospital, Kremlin-Bicêtre Hospital and the
University Hospital in Lille).
The study has also been approved by the ANSM
(Agence nationale de sécurité du medicament et des
produits de santé) on May 2013.
This trial has been registered on Clinicaltrial.gov web-
site under the identification number NCT02041871.
The institutional promoter is the Paul Brousse Univer-
sity Hospital, Villejuif, France. This study received a
grant from the French National Cancer Institute (Institut
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has undergone peer-review by the funding body.
The study products (ORAL IMPACT and IMPACT
CONTROL) were donated by NESTLE Clinical Nutri-
tion, France.
Informed consent will be obtained from each patient
in a written form before enrolment and randomization.
Study status
This study is currently collecting data and there has not
been any publication concerning the analysis of the data
collected until today.
Discussion
The nutritional management is a key element to con-
sider in surgical patients. Protein-energy malnutrition
(PEM) is an imbalance between the intake of nutrients
by an organism and the needs and expenditure of these.
The prevalence of PEM in general surgery and onco-
logical units is high (20% up to 50%) [28-30]: malnutri-
tion was found in 17% to 46% of patients in general
surgery [31-34], in 55% to 80% of patients with gastro-
intestinal cancers and up to 70% of the patients in the
waiting list for liver transplantation [35]. Despite the
high prevalence of PEM in hospital patients and above
all in general surgery and oncological units, malnutrition
remains unappreciated and neglected by clinicians and
can be further aggravated by hospitalization, treatments
and surgical procedures [36].
Several studies have shown that PEM significantly im-
pairs postoperative course and increases morbidity
[37-39], in particular infectious complications, mortality
[40,41], length of stay and costs [42,43] after surgical
procedures. Moreover surgical stress, which is an acute
injury, increases metabolic needs and results in release
of cytokines, which worsen anorexia and muscle wasting.
So malnutrition leads to increased infectious post-operative
complications and surgical stress worsens malnutrition.
In malnourished patients, many studies [44,45] have
shown a benefit of nutritional support before surgery.
Compared with total parenteral nutrition (TPN), enteral
nutrition (EN) in patients undergoing surgery results in
a significantly shorter length of hospital stay, lower inci-
dence of any complications and infectious complications
and lower sepsis scores, but no difference in mortality,
as shown in the meta-analyses by Elia and colleagues
[45]. A systematic screening should be instituted to
identify malnourished patients and propose an appropri-
ate and efficient nutritional support in order to reduce
postoperative complications.
The immunonutrition is the use of nutrients to im-
prove nutritional status and to modulate the immune
and inflammatory responses to a stress. The concept of
immunonutrition arises from the observation that surgicalstress predisposes patients to immune dysfunction and
from the findings that chronic disease-related malnutrition
is tightly linked to the effect of an inflammatory state on
metabolism. Arginine, glutamine, omega-3 fatty acids and
RNA are the key nutrients and immunonutrition could be
administered as enteral or parenteral nutritional supple-
ment. Arginine plays an important role in connective tis-
sue repair and cells proliferation. It is the precursor of
nitric oxide, an important signaling molecule with cyto-
static and cytotoxic effects [46]. Arginine is also an essen-
tial metabolic substrate for immune cells, involved in
normal lymphocyte function, T lymphocytes multiplica-
tion and maturation [47] and in the immune response
again stress and tumors [48]. Furthermore, recent preclin-
ical study has shown that arginine supplementation could
afford some protection from necrosis and apoptosis in is-
chemia/reperfusion liver injury [49] thus helping liver re-
generation after hepatic resection. Omega-3 fatty acids are
anti-inflammatory agents, which decrease the production
of adhesion molecules and inflammatory mediators such
as cytokines. They could reduce the intensity of the in-
flammatory response and modulate immune response to
stress [50]. Nucleotide supplementation has been shown
to improve some aspects of tissue recovery from liver
ischemia-reperfusion injury or radical resection [51] and
to modulate TH1/TH2 balance [52].
Several studies [19,21,22] have just analyzed the impact
of the immunonutrition in the modulation of inflamma-
tory response and immune function after surgical proce-
dures. ORAL IMPACT® (Nestlé Nutrition) is the most
frequently used product in these trials. In these studies
immunonutrition showed a significantly decrease of post-
operative infectious complications, length of hospital stay
and care costs, regardless of the baseline nutritional status
of the patients. The meta-analysis by Cerantola et al. [53]
has selected 21 randomized controlled trials, enrolling a
total of 2730 patients, from more than six-hundred re-
cords identified in the literature, to determine the impact
of perioperative immunonutrition in gastrointestinal sur-
gery: immunonutrition significantly reduced overall com-
plications and postoperative infection when used before
surgery, both before and after operation, or after surgery,
led to a shorter hospital stay but had no influence on mor-
tality. Finally in the study of Bozzetti et al. [54] on 1410
subjects undergoing major abdominal surgery for gastro-
intestinal cancer, nutritional support reduced morbidity
versus standard intravenous fluids with an increasing
protective effect of total parenteral nutrition, enteral nu-
trition, and immune-enhancing enteral nutrition. This ef-
fect remained valid regardless the severity of risk factors
identified at the multivariate analysis and it was more evi-
dent by considering infectious complications only.
The use of immunonutrition in liver surgery has been
poorly studied and till now no recommendation is
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uated the effects of immunonutrition before hepatec-
tomy on postoperative outcomes. In this randomized
controlled trial 26 patients undergoing liver resections
for liver tumours were randomized to immunonutrition
and control groups each consisting of 13 patients. The
study failed to show any significant difference in postop-
erative complications or duration of postoperative hos-
pital stay because a lack of power. Two more studies, by
Fan [56] and Okabayashi [57], have analyzed the interest
of a preoperative enriched nutritional support (branched
chain amino acids-enriched nutrient support) for patients
undergoing liver resection for hepatocellular carcinoma
with cirrhosis and have shown a significant reduction of
postoperative infectious complications.
To date, the effects of preoperative oral immunonutri-
tion (ORAL IMPACT) in non-cirrhotic patients under-
going liver resection for cancer are unknown. As seen in
major gastrointestinal surgery, this treatment could sig-
nificantly reduce postoperative infectious complications,
length of hospital stay and care costs. Therefore the
present trial is designed to evaluate whether the admin-
istration of a short-term preoperative oral immunonutri-
tion can reduce postoperative morbidity in non-cirrhotic
patients undergoing liver resection for cancer.
Abbreviations
ASA score: American Society of Anesthesiologists Score; ICU: Intensive care
unit; CLM: Colorectal liver metastases; HCC: Hepatocellular carcinoma;
EN: Enteral nutrition; TPN: Total parenteral nutrition; MODS: Multiple organ
dysfunction syndrom; PEM: Protein-energy malnutrition; POD: Postoperative
day; POC: Postoperative complications; LR: Liver regeneration; MNA-SF: Mini
nutritional assessment short-form.
Competing interests
Drugs used in this study (ORAL IMPACT and IMPACT CONTROL) have been
donated by Nestlé Clinical Nutrition, France. Nestlé Clinical Nutrition, France
will not interfere with the collection of the data, the analysis of the results
and/or the future publications of the study.
Authors’ contributions
OC and TV wrote the manuscript, OC, TV, DCa conceived of the study, were
involved in the study design and drafted the manuscript, HA helped to
conceive the study and was the statistical advisor, OC, TV, GP, EV, ASC, RA,
DCh, AS, OSo, OSc, DA, CS, SB, PG, JCV, LH, EB, HA, DS, ML, DCa were
involved in study design and inclusion of patients in the trial, DCa is the
study coordinator, obtained the grant and is responsible for the present
paper. All authors read and approved the final manuscript.
Acknowledgements
We thank the sources of funding:
The ‘Programme Hospitalier de Recherche Clinique’ from the French National
Cancer Institut (INCA): funding of design, collection, analysis and
interpretation of the data.
Nestlé Nutrition, France for drug donation and transport.
Author details
1Centre Hépato-biliaire, Paul Brousse Hospital - APHP, 12-14 Avenue Paul
Vaillant Couturier, 94800 Villejuif, France. 2Department of Radiology, Paul
Brousse Hospital – APHP, 12-14 Avenue Paul Vaillant Couturier, 94800
Villejuif, France. 3Department of Hepato-biliairy Surgery and Liver
Transplantation, Saint Antoine Hospital - APHP, 184 Rue du Faubourg
Saint-Antoine, 75012 Paris, France. 4Department of Digestive Surgery,Mondor Hospital - APHP, 51 Avenue du Maréchal de Lattre de Tassigny,
94010 Créteil, France. 5Department of Digestive Surgery, Kremlin-Bicêtre
Hospital - APHP, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France.
6Department of Digestive and Hepato-Pancreato-Biliary Surgery,
Pitié-Salpetrière Hospital - APHP, 47-83 Boulevard de l’Hôpital, Paris 75013,
France. 7Department of Digestive Surgery and Transplantation, University
Hospital of Lille, 2 Avenue Oscar Lambret, 59000 Lille, France. 8Clinical
Research Unit Paris Sud, Bicêtre Hospital - APHP, 78 Rue du Général Leclerc,
Le Kremlin Bicêtre 94275, France. 9UMR-S785 Inserm, Villejuif, France.
10UMR-S776 Inserm, Villejuif, France.
Received: 24 July 2014 Accepted: 26 November 2014
Published: 18 December 2014References
1. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O: Seven
hundred forty-seven hepatectomies in the 1990s: an update to evaluate
the actual risk of liver resection. J Am Coll Surg 2000, 191:38–46.
2. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera
C, Weber S, Blumgart LH: Improvement in perioperative outcome after
hepatic resection: analysis of 1,803 consecutive cases over the past
decade. Ann Surg 2002, 236:397–406. discussion 406–7.
3. Adam R, Aloia T, Krissat J, Bralet M-P, Paule B, Giacchetti S, Delvart V, Azoulay
D, Bismuth H, Castaing D: Is liver resection justified for patients with
hepatic metastases from breast cancer? Ann Surg 2006, 244:897–907.
discussion 907–8.
4. Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, Jaeck D, Saric J, Le
Treut YP, Belghiti J, Mantion G, Mentha G: Hepatic resection for
noncolorectal nonendocrine liver metastases: analysis of 1,452 patients
and development of a prognostic model. Ann Surg 2006, 244:524–535.
5. Finch RJB, Malik HZ, Hamady ZZR, Al-Mukhtar A, Adair R, Prasad KR, Lodge
JPA, Toogood GJ: Effect of type of resection on outcome of hepatic
resection for colorectal metastases. Br J Surg 2007, 94:1242–1248.
6. Farid SG, Aldouri A, Morris-Stiff G, Khan AZ, Toogood GJ, Lodge JPA, Prasad
KR: Correlation between postoperative infective complications and long-
term outcomes after hepatic resection for colorectal liver metastasis. Ann
Surg 2010, 251:91–100.
7. Ito H, Are C, Gonen M, D’Angelica M, Dematteo RP, Kemeny NE, Fong Y,
Blumgart LH, Jarnagin WR: Effect of postoperative morbidity on long-term
survival after hepatic resection for metastatic colorectal cancer. Ann Surg
2008, 247:994–1002.
8. Wu CC, Yeh DC, Lin MC, Liu TJ, P’eng FK: Prospective randomized trial of
systemic antibiotics in patients undergoing liver resection. Br J Surg 1998,
85:489–493.
9. Laurent C, Sa Cunha A, Couderc P, Rullier E, Saric J: Influence of
postoperative morbidity on long-term survival following liver resection
for colorectal metastases. Br J Surg 2003, 90:1131–1136.
10. Schiesser M, Chen JWC, Maddern GJ, Padbury RTA: Perioperative morbidity
affects long-term survival in patients following liver resection for
colorectal metastases. J Gastrointest Surg 2008, 12:1054–1060.
11. Chok KS, Ng KK, Poon RT, Lo CM, Fan ST: Impact of postoperative
complications on long-term outcome of curative resection for
hepatocellular carcinoma. Br J Surg 2009, 96:81–87.
12. Kaibori M, Ishizaki M, Matsui K, Kwon A-H: Postoperative infectious and
non-infectious complications after hepatectomy for hepatocellular
carcinoma. Hepatogastroenterology 2011, 58:1747–1756.
13. Togo S, Tanaka K, Matsuo K, Nagano Y, Ueda M, Morioka D, Endo I, Shimada
H: Duration of antimicrobial prophylaxis in patients undergoing
hepatectomy: a prospective randomized controlled trial using flomoxef.
J Antimicrob Chemother 2007, 59:964–970.
14. Hiramatsu K, Nagino M, Kamiya J, Kondo S, Kanai M, Miyachi M, Uesaka K,
Mizuno S, Nimura Y: A new method to prevent wound infection: a
controlled clinical trial in patients with combined liver and bile duct
resection. Langenbecks Arch Surg 1998, 383:437–441.
15. Kanazawa H, Nagino M, Kamiya S, Komatsu S, Mayumi T, Takagi K, Asahara T,
Nomoto K, Tanaka R, Nimura Y: Synbiotics reduce postoperative infectious
complications: a randomized controlled trial in biliary cancer patients
undergoing hepatectomy. Langenbecks Arch Surg 2005, 390:104–113.
16. Sugawara G, Nagino M, Nishio H, Ebata T, Takagi K, Asahara T, Nomoto K,
Nimura Y: Perioperative synbiotic treatment to prevent postoperative
Ciacio et al. BMC Cancer 2014, 14:980 Page 10 of 10
http://www.biomedcentral.com/1471-2407/14/980infectious complications in biliary cancer surgery: a randomized
controlled trial. Ann Surg 2006, 244:706–714.
17. Wiezer MJ, Meijer C, Sietses C, Prins HA, Cuesta MA, Beelen RH, Meijer S, van
Leeuwen PA: Bactericidal/permeability-increasing protein preserves
leukocyte functions after major liver resection. Ann Surg 2000, 232:208–215.
18. Gurusamy KS, Naik P, Davidson BR: Methods of decreasing infection to
improve outcomes after liver resections. Cochrane Database Syst Rev 2011,
11:CD006933.
19. Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V: A
randomized controlled trial of preoperative oral supplementation with a
specialized diet in patients with gastrointestinal cancer. Gastroenterology
2002, 122:1763–1770.
20. Zheng Y, Li F, Qi B, Luo B, Sun H: Application of perioperative
immunonutrition for gastrointestinal surgery: a meta-analysis of
randomized controlled trials. Asia Pac J Clin Nutr 2007, 16:253–257.
21. Senkal M, Zumtobel V, Bauer KH, Marpe B, Wolfram G, Frei A, Eickhoff U, Kemen
M: Outcome and cost-effectiveness of perioperative enteral immunonutrition
in patients undergoing elective upper gastrointestinal tract surgery: a
prospective randomized study. Arch Surg 1999, 134:1309–16.
22. Braga M, Gianotti L, Radaelli G, Vignali A, Mari G, Gentilini O, Di Carlo V:
Perioperative immunonutrition in patients undergoing cancer surgery: results
of a randomized double-blind phase 3 trial. Arch Surg 1999, 134:428–33.
23. Dindo D, Demartines N, Clavien P-A: Classification of surgical complications.
Ann Surg 2004, 240:205–213.
24. Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, Fan ST,
Yokoyama Y, Crawford M, Makuuchi M, Christophi C, Banting S, Brooke-
Smith M, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey J-N, Greig P,
Rees M, Nimura Y, Figueras J, DeMatteo RP, Büchler MW, Weitz J: Bile
leakage after hepatobiliary and pancreatic surgery: a definition and
grading of severity by the International Study Group of Liver Surgery.
Surgery 2011, 149:680–8.
25. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch
M, Makuuchi M, Dematteo RP, Christophi C, Banting S, Usatoff V, Nagino M,
Maddern G, Hugh TJ, Vauthey J-N, Greig P, Rees M, Yokoyama Y, Fan ST,
Nimura Y, Figueras J, Capussotti L, Büchler MW, Weitz J: Posthepatectomy liver
failure: a definition and grading by the International Study Group of Liver
Surgery (ISGLS). Surgery 2011, 149:713–24.
26. Rahbari NN, Garden OJ, Padbury R, Maddern G, Koch M, Hugh TJ, Fan ST,
Nimura Y, Figueras J, Vauthey J-N, Rees M, Adam R, Dematteo RP, Greig P,
Usatoff V, Banting S, Nagino M, Capussotti L, Yokoyama Y, Brooke-Smith M,
Crawford M, Christophi C, Makuuchi M, Büchler MW, Weitz J: Post-hepatectomy
haemorrhage: a definition and grading by the International Study Group of
Liver Surgery (ISGLS). HPB (Oxford) 2011, 13:528–35.
27. Schulz KF, Altman DG, Moher D: CONSORT, Statement: updated
guidelines for reporting parallel group randomised trials. BMJ 2010,
2010(340):c332–c332.
28. Correia MIT, Campos ACL: Prevalence of hospital malnutrition in Latin
America. Nutrition 2003, 19:823–825.
29. Edington J, Boorman J, Durrant ER, Perkins A, Giffin CV, James R, Thomson
JM, Oldroyd JC, Smith JC, Torrance AD, Blackshaw V, Green S, Hill CJ, Berry
C, McKenzie C, Vicca N, Ward JE, Coles SJ: Prevalence of malnutrition on
admission to four hospitals in England. The Malnutrition Prevalence
Group. Clin Nutr 2000, 19:191–5.
30. Rasmussen HH, Kondrup J, Staun M, Ladefoged K, Kristensen H, Wengler A:
Prevalence of patients at nutritional risk in Danish hospitals. Clin Nutr
2004, 23:1009–1015.
31. Spiekerman AM, Rudolph RA, Bernstein LH: Determination of malnutrition
in hospitalized patients with the use of a group-based reference. Arch
Pathol Lab Med 1993, 117:184–186.
32. Neithercut WD, Smith AD, McAllister J, La Ferla G: Nutritional survey of
patients in a general surgical ward: is there an effective predictor of
malnutrition? J Clin Pathol 1987, 40:803–7.
33. Larsson J, Akerlind I, Permerth J, Hörnqvist JO: The relation between nutritional
state and quality of life in surgical patients. Eur J Surg 1994, 160:329–334.
34. McWhirter J, Pennington C: Incidence and recognition of malnutrition in
hospital J. P. McWhirter and C. R. Pennington. BMJ 1994, 308:945–8.
35. Corish CA, Kennedy NP: Review article protein ± energy undernutrition in
hospital in-patients. Br J Nutr 2000, 83:575–591.
36. Spiro A, Baldwin C, Patterson A, Thomas J, Andreyev HJN: The views and
practice of oncologists towards nutritional support in patients receiving
chemotherapy. Br J Cancer 2006, 95:431–434.37. Alves A, Panis Y, Mathieu P, Mantion G, Kwiatkowski F, Slim K: Postoperative
mortality and morbidity in French patients undergoing colorectal
surgery: results of a prospective multicenter study. Arch Surg 2005,
140:278–283. discussion 284.
38. Malone DL, Genuit T, Tracy JK, Gannon C, Napolitano LM: Surgical site
infections: reanalysis of risk factors. J Surg Res 2002, 103:89–95.
39. Peng PD, van Vledder MG, Tsai S, de Jong MC, Makary M, Ng J, Edil BH,
Wolfgang CL, Schulick RD, Choti MA, Kamel I, Pawlik TM: Sarcopenia
negatively impacts short-term outcomes in patients undergoing hepatic
resection for colorectal liver metastasis. HPB (Oxford) 2011, 13:439–46.
40. Slim K, Panis Y, Alves A, Kwiatkowski F, Mathieu P, Mantion G: Predicting
postoperative mortality in patients undergoing colorectal surgery. World
J Surg 2006, 30:100–106.
41. Englesbe M, Patel S, He K: Sarcopenia and post-liver transplant mortality.
J Am Coll Surg 2010, 211(January 2010):271–278.
42. Elia M: Nutrition and health economics. Nutrition 2006, 22:576–8.
43. Heithoff KA, Cuffel BJ, Kennedy S, Peters J: The association between body
mass and health care expenditures. Clin Ther 1997, 19:811–20.
44. Wu G-H, Liu Z-H, Wu Z-H, Wu Z-G: Perioperative artificial nutrition in
malnourished gastrointestinal cancer patients. World J Gastroenterol 2006,
12:2441–4.
45. Elia M, Van Bokhorst-de van der Schueren MA, Garvey J, Goedhart A,
Lundholm K, Nitenberg G, Stratton RJ: Enteral (oral or tube administration)
nutritional support and eicosapentaenoic acid in patients with cancer: a
systematic review. Int J Oncol 2006, 28:5–23.
46. Potenza MA, Nacci C, Mitolo-Chieppa D: Immunoregulatory effects of
L-arginine and therapeutical implications. Curr Drug Targets Immune
Endocr Metabol Disord 2001, 1:67–77.
47. Ochoa JB, Makarenkova V, Bansal V: A rational use of immune enhancing
diets: when should we use dietary arginine supplementation? Nutr Clin
Pract 2004, 19:216–25.
48. Reynolds JV, Daly JM, Shou J, Sigal R, Ziegler MM, Naji A: Immunologic
effects of arginine supplementation in tumor-bearing and non-tumor-
bearing hosts. Ann Surg 1990, 211:202–210.
49. Chattopadhyay P, Shukla G, Wahi AK: Protective effect of L-arginine
against necrosis and apoptosis induced by experimental ischemic and
reperfusion in Rat liver. J Gastroenterol 2009, 15:156–162.
50. Kew S, Mesa MD, Tricon S, Buckley R, Minihane AM, Yaqoob P: Effects of
oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell
composition and function in healthy humans. Am J Clin Nutr 2004,
79:674–81.
51. Suzuki D, Furukawa K, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato
A, Yoshitomi H, Miyazaki M: Effects of perioperative immunonutrition on
cell-mediated immunity, T helper type 1 (Th1)/Th2 differentiation, and
Th17 response after pancreaticoduodenectomy. Surgery 2010, 148:573–81.
52. Grimble GK, Westwood OM: Nucleotides as immunomodulators in clinical
nutrition. Curr Opin Clin Nutr Metab Care 2001, 4:57–64.
53. Cerantola Y, Hübner M, Grass F, Demartines N, Schäfer M: Immunonutrition
in gastrointestinal surgery. Br J Surg 2011, 98:37–48.
54. Bozzetti F, Gianotti L, Braga M, Di Carlo V, Mariani L: Postoperative
complications in gastrointestinal cancer patients: the joint role of the
nutritional status and the nutritional support. Clin Nutr 2007, 26:698–709.
55. Mikagi K, Kawahara R, Kinoshita H, Aoyagi S: Effect of preoperative
immunonutrition in patients undergoing hepatectomy; a randomized
controlled trial. Kurume Med J 2011, 58:1–8.
56. Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J: Perioperative nutritional
support in patients undergoing hepatectomy for hepatocellular
carcinoma. N Engl J Med 1994, 331:1547–52.
57. Okabayashi T, Iyoki M, Sugimoto T, Kobayashi M, Hanazaki K: Oral
supplementation with carbohydrate- and branched-chain amino acid-
enriched nutrients improves postoperative quality of life in patients
undergoing hepatic resection. Amino Acids 2011, 40:1213–20.
doi:10.1186/1471-2407-14-980
Cite this article as: Ciacio et al.: Interest of preoperative
immunonutrition in liver resection for cancer: study protocol of the
PROPILS trial, a multicenter randomized controlled phase IV trial. BMC
Cancer 2014 14:980.
